Claims for Patent: 11,944,594

Summary for Patent: 11,944,594

Title:	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
Abstract:	A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which includes administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death; wherein the subject has no contra-indications to colchicine therapy, and has at least one risk factor; and vii. therapy with at least one drug chosen from aspirin, clopidogrel, statins, beta blockers, calcium blockers, and ACE inhibitors; and wherein the composition reduces the risk of the subject experiencing the at least one cardiovascular event by a greater percentage than a composition that does not include colchicine or the pharmaceutically acceptable salt thereof.
Inventor(s):	Mark Nidorf
Assignee:	Murray and Poole Enterprises Ltd
Application Number:	US18/144,470
Patent Claims:	1. A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which comprises: administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death; wherein the subject has no contra-indications to colchicine therapy, and has at least one risk factor chosen from: i. an age greater than or equal to 35; ii. diabetes; iii. past myocardial infarction; iv. unstable angina; v. coronary bypass surgery; vi. coronary angioplasty; and vii. therapy with at least one drug chosen from aspirin, clopidogrel, statins, beta blockers, calcium blockers, and ACE inhibitors; and wherein the composition reduces the risk of the subject experiencing the at least one cardiovascular event by a greater percentage than a composition that does not include colchicine or the pharmaceutically acceptable salt thereof. 2. The method of claim 1, wherein the composition is in a form of a tablet or a capsule. 3. The method of claim 1, wherein the composition is in a form of a liquid dose, a gel, or a powder. 4. The method of claim 1, wherein the risk of the at least one cardiovascular event is reduced by at least about 10% compared to a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 5. The method of claim 1, wherein the risk of the at least one cardiovascular event is reduced by at least about 20% compared to a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 6. The method of claim 1, wherein the risk of the at least one cardiovascular event is reduced by at least about 30% compared to a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 7. The method of claim 1, wherein the risk of the at least one cardiovascular event is reduced by at least about 40% compared to a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 8. The method of claim 1, wherein the risk of the at least one cardiovascular event is reduced by at least about 50% compared to a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 9. The method of claim 1, wherein the contra-indications to colchicine therapy is chronic kidney disease. 10. The method of claim 1, wherein the subject is from about 35 to about 85 years of age. 11. The method of claim 1, wherein the at least one cardiovascular event is MI. 12. The method of claim 1, wherein the at least one cardiovascular event is stroke. 13. The method of claim 1, wherein the at least one cardiovascular event is coronary revascularization. 14. The method of claim 1, wherein the at least one cardiovascular event is unstable angina requiring hospitalization. 15. The method of claim 1, wherein the at least one cardiovascular event is cardiac arrest. 16. The method of claim 1, wherein the at least one cardiovascular event is cardiovascular death. 17. The method of claim 1, wherein the subject is administered the composition daily for at least 24 months. 18. The method of claim 1, wherein the subject is administered the composition daily for at least 36 months. 19. The method of claim 1, wherein the subject is administered the composition daily for at least 44 months. 20. The method of claim 1, further comprising co-administering to the subject a therapeutically effective amount of a second agent for reducing the risk of the at least one cardiovascular. 21. The method of claim 17, wherein the second agent is a colchicine-compatible statin. 22. The method of claim 18, wherein the statin is chosen from atorvastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, simvastatin, pravastatin, a salt thereof, and any combination thereof. 23. A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which comprises: administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), and co-administering to the subject a therapeutically effective amount of a second agent; wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death; wherein the subject has no contra-indications to colchicine therapy, and has at least one risk factor chosen from: i. an age greater than or equal to 35; ii. diabetes; iii. past myocardial infarction; iv. unstable angina; v. coronary bypass surgery; vi. coronary angioplasty; and vii. therapy with at least one drug chosen from aspirin, clopidogrel, statins, beta blockers, calcium blockers, and ACE inhibitors; and wherein the composition reduces the risk of the subject experiencing the at least one cardiovascular event by a greater percentage than a composition that does not include colchicine or a pharmaceutically acceptable salt thereof. 24. A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which comprises: administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), and continuing orally administering to the subject the composition once per day for a duration ranging from 24 months to 44 months; wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death; wherein the subject has no contra-indications to colchicine therapy, and has at least one risk factor chosen from: i. an age greater than or equal to 35; ii. diabetes; iii. past myocardial infarction; iv. unstable angina; v. coronary bypass surgery; vi. coronary angioplasty; and vii. therapy with at least one drug chosen from aspirin, clopidogrel, statins, beta blockers, calcium blockers, and ACE inhibitors; and wherein the composition reduces the risk of the subject experiencing the at least one cardiovascular event by a greater percentage than a composition that does not include colchicine or a pharmaceutically acceptable salt thereof.